World Congress of Brachytherapy 10-12 May, 2012 - Estro-events.org
World Congress of Brachytherapy 10-12 May, 2012 - Estro-events.org
World Congress of Brachytherapy 10-12 May, 2012 - Estro-events.org
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
S18 <strong>World</strong> <strong>Congress</strong> <strong>of</strong> <strong>Brachytherapy</strong> 20<strong>12</strong><br />
for the remaining <strong>12</strong>%. Vaginal personalized mould was used in the<br />
majority <strong>of</strong> applications (95%), with an intracavitary technique in all<br />
cases except two. The doses delivered (EBRT + BT, in EqD2) were<br />
67.1+/6.4 Gy (α/β=<strong>10</strong>) to 90% <strong>of</strong> the IRCTV, 78.1+/9.6 Gy (α/β=<strong>10</strong>)<br />
to 90% <strong>of</strong> the HRCTV. The D2cc for the bladder, rectum and sigmoid<br />
were 67.8+/6.7 Gy, 58.8+/5.9 Gy and 58.3 Gy+/5.7 (α/β=3)<br />
respectively. Sixtyone patients (37%) underwent a radical<br />
hysterectomy. Macroscopic residual disease was found in 13 cases.<br />
With a median followup <strong>of</strong> 36 months (579), 45 patients had<br />
relapsed. Twelve local relapses were reported (5 central and 7 lateral<br />
+/ central), <strong>of</strong> which 4 were isolated. There were 22 nodal failures<br />
(<strong>10</strong> pelvic and <strong>12</strong> paraaortic) and 28 metastatic relapses. At the time<br />
<strong>of</strong> failure, 70.4% <strong>of</strong> the patients had distant metastasis, and this was<br />
isolated in more than a half. The 3 year OS and DFS were 84% and 73%<br />
respectively. Local control was 92% and pelvic control was 86%. Local<br />
control decreased in relation to the initial tumour width: 97% for<br />
Change language